 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kala Pharmaceuticals price target lowered to $22 from $24 at H.C. Wainwright

-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ---- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with...

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is...

Sidoti Events, LLCs Virtual August Micro-Cap Conference

ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will change ...

Kala Pharmaceuticals Announces Name Change to KALA BIO

ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement...

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as inducement awards outside the Companys Amended and Restated 2017 Equity Incentive ...

ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present ...

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Banque Cantonale Vaudoise trimmed its position in Kala Pharmaceuticals, Inc. (NASDAQ:KALA  Get Rating) by 98.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities  Exchange Commission. The firm owned 1,508 shares of the companys...

Banque Cantonale Vaudoise Trims Stock Holdings in Kala Pharmaceuticals, Inc. (NASDAQ:KALA)

Wedbush analyst Andreas Argyrides reiterated a Buy rating on Kala Pharmaceuticals (KALA Research Report) today and set a price target of $42.00. ... Wedbush analyst Andreas Argyrides reiterated a Buy rating on Kala Pharmaceuticals (KALA &#8211...

Kala Pharmaceuticals (KALA) Gets a Buy from Wedbush

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Watchers	9,215
52-Wk Low	$3.54
52-Wk High	$56.72

Market Cap	$16.29M
Volume (M)	21,096.00
52-Wk High	$56.72
52-Wk Low	$3.54

KALA Kala Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals